Human LPAR1/LPA receptor 1 VLP Protein
Catalog No: LPAR1-HP001
- Species
- Human
- Expression System
- HEK293
Product overview
Human LPAR1/LPA receptor 1 VLP Protein is a full-length multi-pass membrane protein displayed in a VLP format for antibody discovery, binding assays and method development. Recombinant Human LPAR1/LPA receptor 1 VLP is expressed from HEK293. It contains Met1-Val364 (It may have cross reaction with anti-His antibody) (accession: Q92633-1).
Product Details
- Molecular Aliases
- LPA receptor 1; LPA-1; EDG2; LPA1; EDG-2; GPCR26; GPR26; LPAR1
- Protein Length
- Met1-Val364
- Expression System
- HEK293
- Theoretical Molecular Weight
- The target protein has a predicted MW of 43.1 kDa.
- Purity
- > 90% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22μm filtered solution in PBS, 300mM L-arginine (pH 7.4). Notice: If you need it for immunization, water-soluble adjuvant is recommended.
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Aliquot where appropriate and minimize freeze-thaw cycles.
Background
Lysophosphatidic acid receptor 1 (LPAR1) is one of the G protein-coupled receptors and binds with lysophosphatidic acid (LPA). It is involved in diverse biological functions, including chemotaxis, proliferation, cell differentiation, platelet aggregation, and tumor progression. A set of papers indicated that LPAR1 is a prognostic biomarker in various cancers and takes an important part in the development of prostate cancer.
References
- Shi J, Jiang D, Yang S, Zhang X, Wang J, Liu Y, Sun Y, Lu Y, Yang K. LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. Front Oncol. 2020 Jun 10;10:846. doi: 10.3389/fonc.2020.00846. PMID: 32656075; PMCID: PMC7325998.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.